52 Quick summary: A new clinical study has identified a previously unrecognised biological mechanism involving the RNA molecule PVT1 and the protein STC1 that significantly accelerates the proliferation and spread of gastric cancer cells. Tissue sample analysis confirms that elevated levels of this protein are directly associated with advanced tumour stages and lymph node metastasis, while blocking the pathway successfully reverses these aggressive migratory effects in experimental models. For oncological healthcare practice and public health policy, these findings offer a vital avenue towards developing supplementary diagnostic biomarkers and targeted therapies to combat advanced metastatic disease and improve survival rates for patients. A study published in Current Molecular Pharmacology has identified a previously unrecognised mechanism through which the long non-coding RNA PVT1 and the translation initiation factor EIF4A1 may contribute to the spread of gastric cancer. Researchers at Shihezi University found that PVT1 binds to the N-terminal domain of EIF4A1, leading to increased expression of the secreted glycoprotein STC1. Elevated STC1 levels were shown to activate the Notch1 signalling pathway and promote epithelial-mesenchymal transition, a biological process associated with cancer progression. Together, these effects significantly increased tumour cell migration, invasion, and proliferation in experimental models. As one of the leading causes of cancer deaths worldwide, gastric cancer is notoriously difficult to treat once it metastasises. In the UK, the NHS diagnoses roughly 6,500 new cases annually, with survival relying heavily on catching the disease before it spreads beyond the stomach. While surgery, chemotherapy, and targeted therapies work well early on, effective options for advanced, metastatic stages remain severely limited. Using 4D-DIA quantitative proteomics and mass spectrometry, the research team identified STC1 as a key downstream effector of the PVT1–EIF4A1 signalling axis. Immunohistochemical analysis of 183 gastric cancer tissue samples showed that STC1 was significantly upregulated in tumour tissue and was associated with lymph node metastasis, histological subtype, and tumour stage. In mouse models of lung metastasis, simultaneous overexpression of PVT1 and EIF4A1 resulted in the highest levels of STC1 expression and the greatest number of metastatic lesions. Conversely, when STC1 was knocked down in cells overexpressing both PVT1 and EIF4A1, researchers observed a reversal of the enhanced migratory and proliferative effects. Activation of the Notch1 pathway and epithelial-mesenchymal transition markers was also suppressed. The study highlights how measuring STC1 levels could serve as a valuable tool for tracking cancer progression. Patient tissue analysis revealed a clear link between high STC1 expression and advanced disease, including lymph node metastasis. In the future, clinicians could track this biomarker alongside existing tools to better assess patient risk. “Our findings demonstrate that STC1 acts as a critical mediator of the PVT1-EIF4A1 oncogenic axis in gastric cancer,” said corresponding author Dongmei Li of Shihezi University. “Targeting this pathway, particularly STC1 or the PVT1-EIF4A1 interaction, may offer new therapeutic opportunities for patients with aggressive, metastatic gastric cancer.” The authors note that future research must explore the tumour microenvironment and use multi-omics data to sharpen precision medicine. They emphasise that these findings require validation in larger patient cohorts and prospective clinical trials before they can guide routine treatments.